IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

DERENZINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.768
NA - Nord America 4.736
EU - Europa 4.584
SA - Sud America 556
Continente sconosciuto - Info sul continente non disponibili 512
AF - Africa 91
OC - Oceania 69
Totale 15.316
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.535
CN - Cina 1.618
SG - Singapore 1.311
IT - Italia 933
DE - Germania 891
GB - Regno Unito 558
HK - Hong Kong 486
BR - Brasile 432
RU - Federazione Russa 421
FR - Francia 418
SE - Svezia 347
BD - Bangladesh 303
VN - Vietnam 279
IN - India 214
ES - Italia 206
IE - Irlanda 196
JP - Giappone 136
ID - Indonesia 128
CA - Canada 113
FI - Finlandia 110
NL - Olanda 103
CH - Svizzera 89
TR - Turchia 67
AU - Australia 63
MX - Messico 50
PL - Polonia 49
GR - Grecia 44
KR - Corea 41
BE - Belgio 40
AR - Argentina 37
AT - Austria 35
CI - Costa d'Avorio 29
EC - Ecuador 23
CO - Colombia 22
IR - Iran 20
TW - Taiwan 20
PT - Portogallo 19
ZA - Sudafrica 19
DK - Danimarca 18
IQ - Iraq 16
NO - Norvegia 16
PH - Filippine 16
PK - Pakistan 15
CZ - Repubblica Ceca 14
UA - Ucraina 14
CL - Cile 11
HU - Ungheria 11
IL - Israele 11
JO - Giordania 11
MA - Marocco 11
TH - Thailandia 10
VE - Venezuela 10
UZ - Uzbekistan 9
AM - Armenia 8
BA - Bosnia-Erzegovina 8
EG - Egitto 8
NP - Nepal 8
PE - Perù 8
BG - Bulgaria 7
CR - Costa Rica 7
EE - Estonia 7
JM - Giamaica 7
MY - Malesia 7
TN - Tunisia 7
KZ - Kazakistan 6
SA - Arabia Saudita 6
NZ - Nuova Zelanda 5
RO - Romania 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
KE - Kenya 4
LT - Lituania 4
HR - Croazia 3
LU - Lussemburgo 3
OM - Oman 3
PR - Porto Rico 3
PS - Palestinian Territory 3
PY - Paraguay 3
SV - El Salvador 3
AZ - Azerbaigian 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GH - Ghana 2
GT - Guatemala 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MK - Macedonia 2
MM - Myanmar 2
MU - Mauritius 2
NG - Nigeria 2
NI - Nicaragua 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BB - Barbados 1
BM - Bermuda 1
Totale 14.786
Salva come PNG Salva come JPEG
Città #
Singapore 704
Frankfurt am Main 573
Ashburn 543
Hong Kong 410
Southend 404
San Jose 310
Council Bluffs 270
Milan 269
Dallas 264
Beijing 250
Chandler 222
Fairfield 218
Dublin 196
Santa Clara 161
Princeton 158
Los Angeles 139
Moscow 119
Hefei 117
New York 101
Jakarta 97
Seattle 95
Wilmington 95
Buffalo 91
Shanghai 91
Houston 89
Guangzhou 88
Lauterbourg 86
Woodbridge 86
Ho Chi Minh City 84
Bengaluru 83
Cambridge 79
Hanoi 78
Helsinki 78
Des Moines 69
Rome 65
Ann Arbor 60
Barcelona 57
Tokyo 45
São Paulo 44
Tianjin 42
Eitensheim 39
Cangzhou 38
Munich 38
Nuremberg 38
Columbus 36
Hangzhou 34
Boardman 31
Nanjing 31
Paris 30
Shenzhen 30
Abidjan 29
Central District 29
Madrid 29
San Diego 29
Chicago 28
Istanbul 28
Berlin 27
Lugano 27
Seoul 26
London 25
Naples 25
Toronto 25
Vienna 24
Atlanta 23
Redwood City 23
Sydney 23
The Dalles 23
Washington 23
Bologna 22
Warsaw 21
Phoenix 20
Boston 19
Wuhan 19
Athens 18
Brooklyn 17
Montreal 17
Bari 16
Belo Horizonte 16
Brussels 16
Mumbai 16
North Bergen 16
Rochester 16
Florence 15
Haiphong 15
Southampton 15
Thessaloniki 15
Trieste 15
Turin 15
Zurich 15
Norwalk 14
Silver Spring 14
Catania 13
Lappeenranta 13
Philadelphia 13
Ankara 12
Brisbane 12
Denver 12
Genoa 12
Hanover 12
Melbourne 12
Totale 8.334
Salva come PNG Salva come JPEG
Nome #
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 2.136
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 388
[¹⁸ F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma [$\less$sup$\greater$18$\less$/sup$\greater$F]-{FDG} {PET} radiomic model as prognostic biomarker in diffuse large B-cell lymphoma] 378
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 326
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 311
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma 305
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade 250
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL 242
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors 242
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 236
Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma 227
BIA-ALCL in patients with genetic predisposition for breast cancer: our experience and a review of the literature 223
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 214
Influence of Donor and Recipient Gender on Telomere Maintenanceafter Umbilical Cord Blood Cell Transplantation: A Study by the GruppoItaliano Trapianto Di Midollo Osseo 200
Gemcitabine as single agent in pretreated T-cell lymphoma patients: Evaluation of the long-term outcome 197
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 190
Peripheral t‐cell lymphoma, not otherwise specified : Clinical manifestations, diagnosis, and future treatment 183
Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases 182
Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450) 182
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma : the Italian experience and results of its use in daily clinical practice outside clinical trials 176
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics 174
Bronchus-associated lymphoid tissue lymphomas : an update of a rare extranodal maltoma 165
Blastic plasmacytoid dendritic cell neoplasm : State of the art and prospects 163
Y-90-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment 161
Phase II trial of short-course R-Chop followed by 90Y- ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients 159
Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients 158
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 158
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 155
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma 154
Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular Lymphoma 154
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study 150
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms 148
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: Experience on seven patients 146
Characterization of a c-Rel inhibitor that mediates anticancer properties in hematologic malignancies by blocking NF-κB-controlled oxidative stress responses 143
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 142
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies 141
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients 140
Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study 138
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma 138
Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era 137
Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma 133
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: Multicentric study 132
Predictive and prognostic molecular factors in diffuse large b-cell lymphomas 132
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 131
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13) 129
Plasmablastic lymphoma : One or more tumors? 125
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma 124
Treatment of colorectal cancer liver metastases 123
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 122
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation inFollicular Lymphoma 121
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis : a case report and a review of literature 121
The histone deacetylase inhibitor entinostat (sndx-275) induces apoptosis in hodgkin lymphoma cells and synergizes with bcl-2 family inhibitors 117
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma 117
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma) 116
An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy 113
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma 113
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases 108
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 108
Targeting the JAK-STAT pathway in lymphoma: A focus on pacritinib 107
Predicting treatment outcome in classical Hodgkin lymphoma: Genomic advances 106
Treating hematological malignancies with drugs inhibiting ribosome biogenesis : When and why 105
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: Evaluation of the long-term outcome 102
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study 100
Bendamustine: Role and evidence in lymphoma therapy, an overview 98
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 trial 96
Dissecting diffuse large b-cell lymphomas of the “not otherwise specified” type: The impact of molecular techniques [version 1; referees: 2 approved] 95
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: Retrospective monocentric analysis of 14 patients 90
Treatment of hepatic metastases from colorectal cancer: Many doubts, some certainties 90
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma 89
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 88
A phase ii trial of short course fludarabine, mitoxantrone, rituximab followed by 90y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma 88
Association of essential thrombocythemia and non-Hodgkin lymphoma: A single-centre experience 86
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 85
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: A multicenter retrospective study 85
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 83
Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients 82
Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma 81
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly 79
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified 78
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 Case reports 77
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma 77
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma 77
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ) 74
Hairy cell leukemia with an atypical extranodal presentation: A clinicopathological analysis of four cases 74
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission 73
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin 72
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma 70
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin 69
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma 68
Non-hodgkin lymphomas presenting as soft tissue masses: A single center experience and meta-analysis of the published series 68
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge 65
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients 64
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma 64
Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease 63
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia 63
Primary bone lymphoma: Evaluation of chemoimmunotherapy as front-line treatment in 21 patients 62
Extranodal marginal zone B-cell lymphoma of the lung: Experience with fludarabine and mitoxantrone-containing regimens 60
Slow evolution of liver metastasis from colon cancer 60
The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines 51
Gemcitabine 48
Totale 15.309
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.074
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.074
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.246 0 0 59 131 74 77 70 166 170 159 81 259
2022/20231.557 200 122 177 105 104 262 74 104 126 78 120 85
2023/20241.768 89 129 145 99 249 126 154 149 75 149 180 224
2024/20252.765 165 377 145 216 144 143 145 277 132 254 267 500
2025/20265.572 551 396 626 474 357 329 654 231 689 349 451 465
2026/2027624 285 330 9 0 0 0 0 0 0 0 0 0
Totale 15.316